Report Categories

According to our (Global Info Research) latest study, the global Gene Therapy Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

Add To Cart

According to our (Global Info Research) latest study, the global AAV Gene Therapy Drugs market size was valued at US$ 1564 million in 2023 and is forecast to a readjusted size of USD 8306 million by 2030 with a CAGR of 25.7% during review period.

USD3480.00

Add To Cart

The global AAV Gene Therapy Drugs market size is expected to reach $ 8306 million by 2030, rising at a market growth of 25.7% CAGR during the forecast period (2024-2030).

USD4480.00

Add To Cart

AAV vector-based gene therapy drugs are a class of therapeutic agents used in the treatment of genetic disorders and certain diseases These drugs utilize AAV vectors, which are small, non-enveloped viruses that have a low pathogenic profile and are capable of delivering genetic material into host cells. The genetic material, which be a functional gene or a therapeutic gene, is inserted into the AAV vector and then introduced into the patient's cells, where it is intended to correct genetic mutations or produce therapeutic proteins. AAV vector-based gene therapy has shown promising results in clinical trials for conditions such as Leber congenital amaurosis, spinal muscular atrophy, and certain retinal diseases.

USD4480.00

Add To Cart

Retrovirus-based gene therapy drugs are drugs that use retroviruses as vectors to introduce normal or modified genes into patient cells to treat genetic diseases, cancer and other diseases. Retroviruses occur naturally in some animals and can reverse-transcribe RNA into DNA and insert into the genome of host cells. In gene therapy, scientists take advantage of this feature to load therapeutic genes into retroviral vectors, allowing them to enter the patient's cells and express the required proteins to achieve therapeutic purposes.

USD4480.00

Add To Cart

AAV vector-based gene therapy drugs are a class of therapeutic agents used in the treatment of genetic disorders and certain diseases These drugs utilize AAV vectors, which are small, non-enveloped viruses that have a low pathogenic profile and are capable of delivering genetic material into host cells. The genetic material, which be a functional gene or a therapeutic gene, is inserted into the AAV vector and then introduced into the patient's cells, where it is intended to correct genetic mutations or produce therapeutic proteins. AAV vector-based gene therapy has shown promising results in clinical trials for conditions such as Leber congenital amaurosis, spinal muscular atrophy, and certain retinal diseases.

USD3480.00

Add To Cart

Retrovirus-based gene therapy drugs are drugs that use retroviruses as vectors to introduce normal or modified genes into patient cells to treat genetic diseases, cancer and other diseases. Retroviruses occur naturally in some animals and can reverse-transcribe RNA into DNA and insert into the genome of host cells. In gene therapy, scientists take advantage of this feature to load therapeutic genes into retroviral vectors, allowing them to enter the patient's cells and express the required proteins to achieve therapeutic purposes.

USD3480.00

Add To Cart

Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.

USD4480.00

Add To Cart

Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.

USD3480.00

Add To Cart

The global Gene Therapy Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

USD4480.00

Add To Cart